FIND and BD (Becton, Dickinson and Company; NYSE: BDX), a leading global medical technology company today announced a significant price reduction in the cost of liquid culture testing. The agreement lowers the cost of BD MGIT™ reagents for BD's TB diagnostic technologies, which utilize liquid culture, a key “standard of care” TB testing protocol that provides results far faster than traditional, solid media culture. The liquid culture test, widely used in modern research settings, is particularly effective for stemming the spread of multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) in developing countries.
